Chiesi

Name

Chiesi

Legal name

Chiesi Limited

Website

https://chiesi.uk.com

Company type

Private

Founded year

1935

Operating status

Operating

Headcount range

251–500 employees

Short description

Chiesi is a privately held, family-owned global pharmaceutical group founded in 1935 that develops, manufactures, and commercializes prescription therapies across respiratory health, rare diseases, and specialty care (neonatology and transplantation) across 31 global affiliates and 7 R&D centers.

Ownership category

akta.pro rank

Product category

Specialty Pharmaceuticals

NAICS

Biological Product (except Diagnostic) Manufacturing (325414), Medicinal and Botanical Manufacturing (325411)

SIC

Biological Products, (No Disgnostic Substances) (2836), Medicinal Chemicals & Botanical Products (2833)

akta.pro primary industry

Respiratory & Allergy Pharmaceuticals (HLAIAAAH)

akta.pro secondary industries

Pulmonology & Allergy Specialty Pharmaceuticals (HLAIACAF), Nebulizers & Aerosol Drug Delivery Systems (HLAHAIAJ)

Keywords

• Respiratory pharmaceuticals
• Rare disease therapies
• Neonatal care medicines
• Inhaled asthma treatments
• Enzyme replacement therapy

Headquarters

HQ city

Manchester

HQ country

United Kingdom

HQ region

Europe

Offices8 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Supply Chain, Marketing or Sales, Infrastructure

Revenue model

1. Pharmaceutical Product Sales: Chiesi generates revenue through development, manufacturing, and sale of prescription pharmaceutical products in respiratory health, rare diseases, and specialty care including neonatology and organ transplantation. Products are sold directly to healthcare systems, hospitals, pharmacies, and through NHS procurement.
2. Rare Disease Portfolio Revenue: Revenue from rare disease treatments including Elfabrio ($49 million in 2025 sales), EKTERLY/sebetralstat ($49.1 million in 2025 following US launch), and lomitapide. Strategic goal to reach €6 billion in revenue by 2030.

Pricing tiers

Go-to-market motion2 records

Distribution channels3 records

Marketing channels5 records

Core offering

Chiesi develops, manufactures, and commercializes prescription pharmaceutical products across three core therapeutic franchises: Air (respiratory health including asthma and COPD treatments delivered via pMDIs, DPIs, and nebulizers), Rare (therapies for rare and ultra-rare diseases including Fabry disease, HoFH, hereditary angioedema, lipodystrophy, cystinosis, and LHON), and Care (specialty products for neonatology and organ transplantation). The company also operates digital health initiatives including AI-powered vocal biomarker pilots and the Carbon Minimal Inhaler program targeting 90% carbon footprint reduction in respiratory treatments.

Product overview

Chiesi is a research-oriented international biopharmaceutical group with a diversified portfolio organized around three core disease areas: Air (respiratory health including asthma and COPD), Rare (rare and ultra-rare diseases), and Care (specialty care including neonatology and organ transplantation). The company operates both a core pharmaceutical portfolio and a dedicated Chiesi Global Rare Diseases business unit. The respiratory portfolio includes inhaled therapies delivered via multiple device formats: pMDI inhalers (Clenil Modulite, Fostair pMDI, Trimbow pMDI), dry powder inhalers (Fostair NEXThaler, Trimbow NEXThaler, Atimos Modulite), and nebulized antibiotics (Bramitob, Quinsair). The rare disease portfolio spans enzyme replacement therapies (Elfabrio for Fabry disease, Lamzede for alpha-mannosidosis), oral therapies (LOJUXTA for HoFH, Myalepta for lipodystrophy, Procysbi for cystinosis, Raxone for LHON), and acquired products (EKTERLY for hereditary angioedema). Specialty care includes neonatal products (Curosurf surfactant, Peyona caffeine), transplant immunosuppression (Envarsus tacrolimus), and supporting therapies across cardiovascular, hematology, and dermatology. Chiesi also operates digital health initiatives including the Carbon Minimal Inhaler program targeting 90% carbon footprint reduction, Salesforce-based commercial operations platforms, and AI-powered diagnostic technologies.

Differentiator

Problem solved

Functional benefit

Brands

• Chiesi Global Rare Diseases: Business unit delivering innovative therapies and solutions for people living with rare diseases including Fabry disease, cystinosis, lipodystrophy, and hereditary angioedema.

Products and services

• Clenil Modulite Pressurized metered dose inhaler (pMDI) containing beclometasone in 50mcg, 100mcg, 200mcg, and 250mcg strengths for asthma management. Chiesi's first carbon minimal inhaler candidate, with the HFA-152a formulation submitted to MHRA targeting up to 90% carbon footprint reduction.
• Fostair NEXThaler Dry powder inhaler combining beclometasone and formoterol in 100/6 and 200/6 dose strengths for asthma and COPD management.
• Fostair pMDI Pressurized metered dose inhaler combining beclometasone and formoterol in 100/6 and 200/6 dose strengths for respiratory disease treatment.
• Trimbow Triple combination therapy inhaler containing beclometasone, formoterol, and glycopyrronium available in multiple strengths and delivery formats (NEXThaler DPI and pMDI) for COPD management.
• Atimos Modulite Breath-actuated breath-coordinated modulit inhaler containing formoterol as a long-acting bronchodilator for asthma and COPD.
• Elfabrio (pegunigalsidase alfa) PEGylated enzyme replacement therapy for adult patients with Fabry disease. Plant cell culture-expressed recombinant alpha-galactosidase A enzyme with stabilized pharmacokinetics. Approved with standard 1mg/kg every-two-weeks dosing and additional 2mg/kg every-four-weeks regimen for ERT-stable patients, reducing infusion frequency from 26 to 13 annually.
• LOJUXTA (lomitapide) Microsomal triglyceride transfer protein inhibitor for Homozygous Familial Hypercholesterolaemia (HoFH). Originally approved for adults in 2013, with European Commission approval extended in June 2026 to include children 5 years and older.
• Myalepta (metreleptin) Recombinant human leptin analog for treatment of lipodystrophy. Chiesi Global Rare Diseases presented metreleptin research at ENDO 2026 across generalized and partial lipodystrophy, including combination therapy with GLP-1 receptor agonists.
• EKTERLY (sebetralstat) First and only oral, on-demand plasma kallikrein inhibitor for acute hereditary angioedema (HAE) attacks in patients 12 years and older. Acquired through Chiesi's $1.9 billion acquisition of KalVista Pharmaceuticals in June 2026. Approved in US, UK, EU, Japan, Australia, Switzerland, and Singapore. Generated $49 million in 2025 sales.
• Lamzede (velmanase alfa) Recombinant human alpha-mannosidase enzyme replacement therapy for alpha-mannosidosis, a rare lysosomal storage disorder.
• Procysbi (mercaptamine bitartrate) Delayed-release cysteamine bitartrate formulation for nephropathic cystinosis, reducing cystine accumulation in lysosomes.
• Raxone (idebenone) Synthetic short-chain coenzyme Q10 analog for Leber hereditary optic neuropathy (LHON). Received Complete Response Letter from FDA regarding New Drug Application.
• Curosurf (poractant alfa) Natural porcine pulmonary surfactant for treatment of respiratory distress syndrome in premature infants.
• Peyona (caffeine citrate) Caffeine citrate solution for primary apnea of premature newborns.
• Envarsus (tacrolimus monohydrate) Once-daily tacrolimus formulation for immunosuppression in kidney and liver transplant recipients.
• Bramitob (tobramycin) Inhaled tobramycin solution for Pseudomonas aeruginosa infection management in cystic fibrosis patients.
• Quinsair (levofloxacin) Inhaled levofloxacin for chronic Pseudomonas aeruginosa lung infections in cystic fibrosis patients.
• Ferriprox (deferiprone) Oral iron chelator for treatment of iron overload in thalassemia and other transfusion-dependent anemias.
• Filsuvez Gel Topical gel containing birch bark extract for junctional and dystrophic epidermolysis bullosa.
• Kengrexal (cangrelor) Intravenous P2Y12 platelet receptor antagonist for percutaneous coronary intervention.
• Cardioplen XL (felodipine) Extended-release calcium channel blocker for hypertension and angina in 2.5mg, 5mg, and 10mg strengths.
• Monomax XL (isosorbide mononitrate) Extended-release nitrate for prevention of angina pectoris.
• Clipper (budesonide) Budesonide formulation for inflammatory bowel conditions.
• Natecal D3 Calcium carbonate and cholecalciferol combination for calcium deficiency.

Quantifiable outcome

• Reduces carbon footprint of pMDIs by up to 90% compared to current HFA-134a inhalers
• +4 more outcomes

Named customers3 records

Segments4 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability2 records

Feature3 records

Partnerships

Eight partnerships are on record, tiered core, major and minor.

• KalVista PharmaceuticalscoreOthers · 29 April 2026Acquisition completed June 11, 2026 for $1.9 billion ($27 per share), making KalVista a wholly owned subsidiary. Acquisition adds EKTERLY (sebetralstat), first oral on-demand treatment for hereditary angioedema, to Chiesi's rare disease portfolio. Approximately 77.8% of shares tendered.
• SalesforcemajorTechnology or Integration · 20 April 2026Chiesi selected Salesforce Agentforce Life Sciences platform to transform commercial operations, serving 3,300 users with unified data management through Data 360, AI-assisted field team support, and scalable commercial operations management. Partnership supports digital transformation amid geopolitical, regulatory, and supply chain pressures.
• NHS EnglandcoreStrategic or Co-development Partner · 18 March 2026£10 million Respiratory Transformation Partnership co-funded by NHS England and four pharmaceutical companies (AstraZeneca, Chiesi, GSK, Sanofi) to transform asthma and COPD care by shifting treatment from hospitals to local communities. Partnership uses data and digital tools to improve diagnosis and expand access to biologic medicines.
• BespakcoreStrategic or Co-development Partner · 11 March 2026Expanded partnership to increase pMDI manufacturing capacity at Bespak's Holmes Chapel site supporting Chiesi's Carbon Minimal Inhaler program. Partnership aims to reduce carbon footprint of pMDIs by up to 90% through transition to low GWP propellants. Reinforces both companies' sustainability commitments with Chiesi targeting Net Zero by 2035 and Bespak holding SBTi-validated decarbonization targets.
• Protalix BioTherapeuticscoreStrategic or Co-development PartnerGlobal partnership for development and commercialization of pegunigalsidase alfa (Elfabrio) for Fabry disease. Chiesi received $25 million milestone payment following EC approval of E4W dosing regimen. Protalix manufactures using proprietary plant cell-based expression system ProCellEx.
• VoiceMedminorStrategic or Co-development PartnerSix-month clinical pilot with Rome-based digital health startup to explore AI-powered vocal biomarker technology for early detection of COPD and chronic respiratory diseases via smartphone voice recordings.
• Gossamer BiocoreStrategic or Co-development PartnerGlobal collaboration with Gossamer Bio for joint development of seralutinib in pulmonary arterial hypertension. Phase 3 PROSERA study completed with +13.3m improvement in Six-Minute Walk Distance at Week 24. Discussions with FDA ongoing for potential NDA submission.
• NHS Trusts (Multiple)coreStrategic or Co-development PartnerMultiple collaborative working projects with NHS trusts including Manchester University NHS Foundation Trust (PIONEER post-transplant project), Hull University Teaching Hospitals (FRONTIER COPD diagnosis), Wirral Primary Care Collaborative (COMET), Health Innovation Manchester (MISSION), and Academic Health Science Network (NTEC neonatal project).

Scale indicators9 records

Recent moves7 records

Expansion highlights7 records

Market position

Competitive moat5 records

Key risks1 record

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/chiesi-uk
• Facebookfacebook.com/Chiesi-UK-106020785376663

Compliance5 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles12 records

Subsidiaries4 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Chiesi